Form 4: Oruka Therapeutics SVP Arjun Agarwal Executes Stock Sales

Senior Vice President of Finance Arjun Agarwal exercised stock options and sold shares of Oruka Therapeutics under a 10b5-1 plan.

Summary

• Arjun Agarwal, SVP of Finance at Oruka Therapeutics, exercised options to acquire 9,459 shares of common stock.
• The exercise prices for the options were $12.50 and $34.39 per share.
• Following the exercises, Agarwal sold a total of 9,854 shares at prices ranging from approximately $67.87 to $70.86.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan established on February 11, 2026.
• A portion of the sales was executed to satisfy tax withholding obligations related to the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding insider equity management, which carries no inherent positive or negative signal regarding company performance.

Positives

• The executive maintains a significant remaining beneficial ownership of 16,899 shares of common stock.
• The transactions were pre-planned under a Rule 10b5-1 trading plan, indicating systematic rather than reactive selling.

Negatives

• The executive reduced his direct equity stake in the company through these sales.

Risks

• Future share price volatility could impact the value of remaining unvested employee stock options.
• Reliance on Rule 10b5-1 plans does not eliminate the potential for negative market perception regarding insider selling.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of insider transaction activity.

Management Comments

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for corporate executives to manage personal liquidity and tax obligations, and is generally viewed as neutral by the market when pre-planned.

Comparison to Industry Standards

• The use of 10b5-1 plans is consistent with best practices for corporate governance among U.S. publicly traded biotechnology companies.
• The sell-to-cover procedure for tax obligations is a standard industry mechanism for managing equity compensation.

Stakeholder Impact

• Shareholders should note the reduction in insider holdings, though the volume is consistent with standard compensation liquidation.

Next Steps

• Continued vesting of remaining employee stock options according to the 1/48 monthly schedule.

Key Dates

Keywords

Oruka Therapeutics, ORKA, Insider Trading, Form 4, Stock Options, Equity Compensation